导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.96% | 1709/4773 |
| 近一周 | -2.90% | 4380/5465 |
| 近一月 | 0.48% | 559/5421 |
| 近一季 | -2.64% | 1459/5231 |
| 近半年 | -12.13% | 3773/4920 |
| 近一年 | 11.51% | 1021/4394 |
| 近两年 | 46.15% | 1629/2954 |
| 近三年 | 29.08% | 1119/2253 |
| 成立以来 | 75.90% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
9.54% 82/4961 |
-5.88% 3633/5312 |
- - |
- - |
| 2025 | 16.72% 2421/4813 |
-2.07% 2837/3635 |
1.48% 2314/4076 |
10.12% 3321/4524 |
6.65% 350/4813 |
| 2024 | 16.35% 823/3463 |
7.38% 248/2808 |
1.10% 502/3014 |
10.17% 2645/3129 |
-2.72% 2166/3463 |
| 2023 | -0.91% 479/2656 |
13.18% 275/2280 |
0.65% 291/2385 |
-6.06% 1425/2515 |
-7.41% 2140/2655 |
| 2022 | -14.53% 375/2207 |
-8.46% 284/1919 |
4.52% 1005/2016 |
-12.54% 724/2113 |
2.13% 1030/2208 |
| 2021 | 14.40% 332/1822 |
4.94% 127/1255 |
4.53% 877/1330 |
5.96% 248/1466 |
-1.58% 1375/1822 |
| 2020 | 11.48% 826/1250 |
-12.21% 877/1028 |
0.31% 1006/1067 |
13.12% 345/1164 |
11.91% 509/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 富国中证国企一带一路ETF VS. 长安沪深300非周期A(740101) |